February 2023

Presenters at the 2022 San Antonio Breast Cancer Symposium discussed how antibody-drug conjugates have been changing the treatment landscape for patients with breast cancer.

In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall survival rates vs those given intense salvage chemotherapy first.

Recent findings that stratify the use of Bruton tyrosine kinase inhibitors in combination with autologous stem cell transplant were explored during major medical conferences in 2022.